Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) contains betamethasone, chloramphenicol, and lidocaine, a topical combination used for the management of inflamed, infected, and painful skin conditions. Betamethasone reduces inflammation and immune-mediated skin reactions, chloramphenicol provides broad-spectrum antibacterial cover, and lidocaine delivers rapid localised pain and itch relief. This formulation is commonly used in conditions where inflammation, bacterial infection, and discomfort are present simultaneously. Always use Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) exactly as directed by your doctor.

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) is a three-component topical formulation combining anti-inflammatory, antibacterial, and local anaesthetic properties for the management of infected and inflamed skin conditions.

Betamethasone is a potent synthetic corticosteroid that suppresses the inflammatory cascade by inhibiting phospholipase A2 and reducing the production of prostaglandins, leukotrienes, and pro-inflammatory cytokines. It rapidly reduces erythema, swelling, and pruritus in inflammatory dermatoses.

Chloramphenicol is a broad-spectrum bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide chain elongation. It is effective against a wide range of Gram-positive and Gram-negative organisms responsible for superficial skin infections.

Lidocaine is an amide-class local anaesthetic that reversibly blocks voltage-gated sodium channels in peripheral sensory nerve endings, preventing pain signal generation and transmission. Topically applied, it provides rapid relief from pain, burning, and itching at the site of skin injury or inflammation.

Together, these components address inflammation, bacterial infection, and localised pain through distinct and complementary mechanisms.

The uses of Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) are as follows:

Infected Inflammatory Dermatoses

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) is used where skin inflammation is complicated by bacterial superinfection requiring simultaneous anti-inflammatory and antibacterial treatment.

Secondarily Infected Eczema

It is used in eczematous conditions where bacterial infection requires concurrent treatment alongside inflammation management.

Otitis Externa

The combination of anti-inflammatory, antibacterial, and analgesic properties makes it useful in outer ear canal infections and inflammation.

Minor Infected Wounds

It is used to manage pain, inflammation, and bacterial contamination in minor skin injuries with secondary infection.

Seborrhoeic Dermatitis with Secondary Infection

The anti-inflammatory and antibacterial components address both the inflammatory and infective aspects of the condition.

Here are the benefits of Betamethasone + Chloramphenicol + Lidocaine (Lignocaine):

• Simultaneous Anti-inflammatory and Antibacterial Action: Betamethasone and chloramphenicol together address the inflammatory and infective components of skin conditions in a single application.

• Rapid Pain and Itch Relief: Lidocaine provides prompt localised anaesthesia, reducing discomfort and the urge to scratch.

• Broad-Spectrum Antibacterial Cover: Chloramphenicol is effective against a wide range of skin-infecting organisms including both Gram-positive and Gram-negative bacteria.

• Targeted Localised Action: Topical application delivers all three components directly to the site of pathology with minimal systemic absorption.

Like all medicines, Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) may cause side effects in some individuals.

Common Side Effects:

• Mild Stinging or Burning: A transient sensation at the application site may occur, particularly on broken or inflamed skin.

• Skin Dryness: Repeated application may cause mild dryness or tightness of the treated area.

• Mild Erythema: Localised redness at the application site may develop initially.

Uncommon Side Effects:

• Skin Thinning: Prolonged use of betamethasone may cause localised skin atrophy, particularly on thin-skinned areas.

• Contact Dermatitis: Sensitivity reactions to any component may develop with repeated use.

• Folliculitis: Inflammation of hair follicles may occur with extended use.

Serious Side Effects (Require Immediate Medical Attention):

• Severe Allergic Reaction: Swelling, difficulty breathing, or widespread rash requires urgent medical care.

• Skin Superinfection: Development of a secondary fungal or resistant bacterial infection requires prompt review.

• Systemic Corticosteroid Effects: Extensive or prolonged application of betamethasone may cause adrenal suppression, particularly in children.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Apply a thin layer to the affected area as directed, usually once or twice daily.

• Wash and dry hands before and after application.

• Avoid application near the eyes, mouth, or mucous membranes unless specifically directed.

• Do not use for longer than the prescribed duration to minimise corticosteroid-related side effects.

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) works through three complementary mechanisms targeting inflammation, bacterial infection, and localised pain.

Betamethasone binds to intracellular glucocorticoid receptors, suppressing transcription of pro-inflammatory genes and reducing production of prostaglandins, leukotrienes, and cytokines. This rapidly decreases erythema, swelling, and pruritus in inflamed skin.

Chloramphenicol binds to the 50S ribosomal subunit of bacteria, blocking peptide chain elongation and halting protein synthesis. This bacteriostatic action reduces bacterial load and limits the infectious component of skin conditions.

Lidocaine reversibly blocks voltage-gated sodium channels in peripheral sensory nerve endings, preventing depolarisation and the transmission of pain and itch signals to the central nervous system.

A few practical measures can help improve treatment outcomes and ensure safe use of Betamethasone + Chloramphenicol + Lidocaine (Lignocaine):

• Apply to clean, dry skin: Gently cleanse the affected area before application to maximise effectiveness.

• Use the minimum effective amount: A thin layer is sufficient; excessive application increases side effect risk without improving outcomes.

• Do not use on the face for extended periods: Prolonged facial use may cause skin thinning and perioral dermatitis due to betamethasone.

• Do not occlude unless directed: Covering treated skin with bandages significantly increases corticosteroid and chloramphenicol absorption.

• Report lack of improvement promptly: If the infection does not improve within a few days, consult your doctor as resistant organisms may require alternative treatment.

Proper storage is important to maintain the stability and effectiveness of Betamethasone + Chloramphenicol + Lidocaine (Lignocaine):

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep tube tightly closed: Prevents contamination and drying of the formulation between uses.

• Keep out of reach of children: Store safely to prevent accidental ingestion or misuse.

• Check expiry before use: Do not use after the expiry date printed on the packaging.

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) is a topical formulation and is not significantly affected by dietary intake. However:

• Avoid alcohol-based skincare products on treated areas: These may increase skin irritation and dryness alongside this formulation.

• No dietary restrictions required: Topical use does not necessitate changes to eating habits or fluid intake.

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) may interact with the following medicines:

• Other Topical Corticosteroids: Concurrent use increases total corticosteroid exposure and the risk of skin atrophy.

• Other Topical Antibiotics: Combining with other topical antibacterials on the same area may cause irritation or reduce individual effectiveness.

• Antiarrhythmic Medicines: Systemic absorption of lidocaine from excessive application may interact with antiarrhythmic agents.

• Immunosuppressants: Combined use with topical or systemic immunosuppressants may increase infection risk.

Betamethasone + Chloramphenicol + Lidocaine (Lignocaine) should be used carefully in the following conditions:

• Rosacea and Perioral Dermatitis: Topical corticosteroids may worsen or precipitate these conditions.

• Skin Atrophy or Fragile Skin: Pre-existing skin thinning increases the risk of further corticosteroid-induced atrophy.

• Bone Marrow Disorders: Chloramphenicol has been associated with aplastic anaemia with systemic use; topical application carries minimal risk but should be used cautiously in patients with haematological conditions.

• Cardiac Arrhythmias: Systemic absorption of lidocaine from extensive application may affect cardiac conduction in susceptible individuals.

Usually applied once or twice daily to the affected area as directed by your doctor. Treatment duration should not exceed the prescribed period to minimise corticosteroid-related effects.

If a dose is missed, apply it as soon as remembered. Do not double the application to make up for a missed one.